Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: Effect modification or regression to the mean?

References 

1. Addington DE, Labelle A, Kulkarni J, Johnson G, Loebel A, Mandel FS. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. Canadian Journal of Psychiatry. 2009;54(1):46–54
2. Allison PD. Testing for interaction in multiple regression. American Journal of Sociology. 1977;83:144–153
3. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry. 1999;156:1686–1696
4. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596–601
   • MEDLINE
   • CrossRef
5. Arato M, O' Connor R, Meltzer HY for the ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia. International Clinical Psychopharmacology. 2002;17:207–215
   • MEDLINE
   • CrossRef
6. Bland JM, Altman DG. Statistic notes: regression towards the mean. British Medical Journal. 1994;308:1499
7. Campbell DT, Kenny DA. A Primer on Regression Artifacts. New York: The Guilford Press; 1999;
8. Galton F. Regression towards mediocrity in hereditary stature. Journal of the Anthropological Institute. 1886;15:246–263
9. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. New York: Academic Press; 1985;
10. Lane HY, Chang YC, Cheng YC, Liu GC, Lin XR, Chang WH. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. Journal of Clinical Psychiatry. 2003;64:316–320
11. Lee E, Leung CM, Wong E. Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. Journal of Clinical Psychiatry. 2004;65:864–866
12. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine. 2005;353:1209–1223
13. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1–93
    • MEDLINE
    • CrossRef
14. Potkin, S.G., Weiden, P.J., Loebel, A.D., Warrington, L.E., Watsky, E.J., Siu, C.O., 2009. Remission in schizophrenia: 196-week double-blind treatment with ziprasidone versus haloperidol. International Journal of Neuropsychopharmacology 12 (9), 1233–1248.
15. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. Journal of the American Academy of Child and Adolescent Psychiatry. 2002;41(3):337–343
    • Abstract
    • Full Text
    • Full-Text PDF (133 KB)
    • CrossRef
16. Rogers JL, Nicewander WA. Thirteen ways to look at the correlation coefficient. The American Statistician. 1988;42:59–66
17. Shepard DS, Finison LJ. Blood pressure reductions: correcting for regression towards the mean. Preventive Medicine. 1993;12:304–317
18. Simpson GM, Weiden P, Pigott T, Murray S, Siu CO, Romano SJ. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. American Journal of Psychiatry. 2005;162:1535–1538
19. Tu YK, Gilthorpe MS. Revisiting the relation between change and initial value: a review and evaluation. Statistical Medicine. 2007;26:443–457
20. Yudkin PL, Stratton IM. How to deal with regression to the mean in intervention studies. Lancet. 1988;347:241–243
    • CrossRef